logo
Share SHARE
FONT-SIZE Plus   Neg

Ind-Swift Labs Gets US FDA Nod For 5 APIs For Its Derabassi Facility

Pharma major Ind-Swift Laboratories Ltd. has obtained the US FDA nod for its five Active Pharmaceutical Ingredients or APIs manufactured at its Derabassi manufacturing facility.

The products for which the company has obtained the approval are Naratriptan Hydrochloride (anti-migraine), Ropinirole Hydrochloride (anti-Parkinson's disease), Donepezil Hydrochloride (anti-Alzheimer's disease), Acamprosate Calcium (anti-alcohol dependence) and Clarithromycin (Macrolide antibiotic).

With this approval, the company will be able to sell its products in the US market. The worldwide market for these products is $5 billion.

The company's Derabassi facility is already accredited by key accreditation agencies such as TGA, MHRA, COS, KFDA and PMDA.

Commenting on the development, Vice Chairman and Managing Director N.R. Munjal said, "This multi product approval will give multifold aggression to the sales as we have good presence in US through our US subsidiary and we expect this approval to give additional 50 percent to 60 percent growth in US sales."

At the BSE, Ind-Swift Laboratories closed Tuesday's trading at Rs.98.65, up 3.30 percent from the previous close.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Many apps are designed to enhance productivity, simplify social networking or provide other useful benefits. These apps are practical and functional. Others are shaping day-to-day lives. Thanks to these apps, the smartphones have already replaced the watch, calendar, calculator, address book, voice... The global app market would be worth $6.3 trillion by 2021, compared to $1.3 trillion in 2016, according to a new report from analyst firm App Annie. The expected growth in the global app market is said to reflect the significantly increasing number of smartphone owners and their use of mobile apps. Agricultural products giant Monsanto Co. on Wednesday reported a nearly 18 percent increase in profit for the third quarter from last year, reflecting strong sales growth in the agricultural productivity segment and a lower tax provision. Looking ahead, the company affirmed its outlook for fiscal 2017 ongoing earnings.
comments powered by Disqus
Follow RTT